- Home
- GIGM vs LEXX Comparison
GIGM vs LEXX Comparison
Compare GIGM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- LEXX
- Stock Information
- Founded
- GIGM 1998
- LEXX 2004
- Country
- GIGM Taiwan
- LEXX Canada
- Employees
- GIGM N/A
- LEXX N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- LEXX Health Care
- Exchange
- GIGM Nasdaq
- LEXX Nasdaq
- Market Cap
- GIGM 17.0M
- LEXX 16.5M
- IPO Year
- GIGM 2000
- LEXX N/A
- Fundamental
- Price
- GIGM $1.83
- LEXX $1.46
- Analyst Decision
- GIGM
- LEXX Strong Buy
- Analyst Count
- GIGM 0
- LEXX 1
- Target Price
- GIGM N/A
- LEXX $4.00
- AVG Volume (30 Days)
- GIGM 23.8K
- LEXX 194.0K
- Earning Date
- GIGM 10-29-2025
- LEXX 07-14-2025
- Dividend Yield
- GIGM N/A
- LEXX N/A
- EPS Growth
- GIGM N/A
- LEXX N/A
- EPS
- GIGM N/A
- LEXX N/A
- Revenue
- GIGM $3,250,000.00
- LEXX $615,923.00
- Revenue This Year
- GIGM N/A
- LEXX $46.98
- Revenue Next Year
- GIGM N/A
- LEXX $17.26
- P/E Ratio
- GIGM N/A
- LEXX N/A
- Revenue Growth
- GIGM N/A
- LEXX 49.85
- 52 Week Low
- GIGM $1.30
- LEXX $0.77
- 52 Week High
- GIGM $1.89
- LEXX $3.47
- Technical
- Relative Strength Index (RSI)
- GIGM 69.35
- LEXX 80.90
- Support Level
- GIGM $1.61
- LEXX $0.98
- Resistance Level
- GIGM $1.89
- LEXX $1.34
- Average True Range (ATR)
- GIGM 0.09
- LEXX 0.09
- MACD
- GIGM 0.03
- LEXX 0.05
- Stochastic Oscillator
- GIGM 85.71
- LEXX 96.79
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.